US 7968569

I'll search for authoritative information on this specific patent number and check for any 2026 CAFC activity.

Let me look for the actual claim text and any 2026 CAFC docket activity.

Let me check for any 2026 CAFC docket activity and confirm the independent claims.

US Patent 7,968,569 — Analyst Summary

Bibliographic Data

Date discrepancy note: Google Patents and Unified Patents disagree by one day on the priority/filing/grant dates (05-17 vs 05-16, etc.). I have not resolved which is authoritative; there is no material consequence, but I flag it rather than silently picking one.

Abstract (as listed)

"Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed."

Important: The abstract is much broader than the granted claims. The specification is a broad "treat/manage/prevent cancer and angiogenesis disorders" disclosure (a Celgene IMiD platform application, in the WO 2004/043377 family), but the issued claim set was narrowed during prosecution to a specific lenalidomide multiple-myeloma dosing regimen. The title, not the abstract, reflects the actual claimed subject matter.

Independent Claims — Plain-Language Overview

The '569 patent has two independent claims, claim 1 and claim 13 (claims 2–12 depend from claim 1; claims 14+ depend from claim 13). This identification comes from the IPR petition record for the '569 patent (PTAB petition 1518596 / IPR2018-01714 filings).

Claim 1 — Treating multiple myeloma with a cyclic lenalidomide + dexamethasone regimen
A method of treating multiple myeloma, comprising cyclically administering to a multiple-myeloma patient:

• about 5 to about 25 mg per day of lenalidomide (claimed structurally as 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione) or a pharmaceutically acceptable salt thereof,
• for 21 consecutive days followed by 7 consecutive days of rest (a 28-day cycle),
• in combination with 40 mg per day of dexamethasone.

Plain language: give the patient 5–25 mg/day of lenalidomide on a "21 days on / 7 days off" monthly cycle, together with 40 mg/day of dexamethasone.

Claim 13 — Same drug regimen with a specified dexamethasone schedule
A similar independent method claim, but with an explicit dexamethasone dosing pattern: lenalidomide administered for 21 consecutive days, and dexamethasone administered on days 1–4 every 28 days (i.e., a 4-day dexamethasone pulse per cycle rather than a continuous 40 mg/day).

Plain language: the same lenalidomide 21-on/7-off cycle, but dexamethasone is given as a short 4-day burst at the start of each 28-day cycle.

Plain-Language Takeaway

The '569 patent covers a method-of-use/dosing-regimen invention — specifically, using lenalidomide (Revlimid®) at 5–25 mg/day on a 21-day-on/7-day-off cycle, combined with dexamethasone, to treat multiple myeloma. It is not a composition-of-matter patent; the lenalidomide molecule itself is covered by earlier Celgene patents (e.g., US 5,635,517 / 6,281,230 family).

Litigation / Post-Grant Activity

• PTAB IPR2018-01714 (petitioner listed by Unified Patents): Not instituted on the merits.
• IPR filed by Lotus/Alvogen (2017) challenging the '569 patent: denied by the PTAB on 14 March 2019 for insufficient evidence (per Taiwanese IPO disclosure materials).
• District court suits (D.N.J. and N.D. W. Va.) listed against the '569 patent include: 2:12-cv-04571, 2:16-cv-07704, 2:17-cv-02528, 2:17-cv-06163, 2:17-cv-06842, 2:18-cv-08964, 2:18-cv-11518, 2:18-cv-11630, 2:19-cv-14731, 2:19-cv-15449, 2:20-cv-00315, 2:20-cv-07759, 2:20-cv-08570, 2:20-cv-14389, 2:21-cv-10398, 2:21-cv-11261, 2:21-cv-12927, 2:21-cv-20099, 2:21-cv-20459, 2:22-cv-02952, and 1:20-cv-00003. These were ultimately resolved through settlements/consent judgments permitting generic lenalidomide entry in limited volumes from March 2022.
• CAFC 2026 dockets: I found no Federal Circuit appeal in 2026 specifically involving US 7,968,569. My searches surfaced only older Federal Circuit activity in the broader Celgene/Revlimid patent wars (e.g., REMS-patent appeals) and the 2023 antitrust complaint, not a 2026 appeal of the '569 patent. Because the patent expired 2023-10-07 and the associated litigation was settled, a fresh 2026 CAFC appeal would be unusual.

Uncertainty / Caveats

1. Claims: The authoritative Google Patents text supplied to me is truncated before the claims section, so I could not read the claims directly from the patent document. The claim 1 and claim 13 wording above comes from PTAB IPR filings and district-court briefing, which quote the claims verbatim; I regard that as reliable but not a substitute for the printed claim set. If exact claim language is critical, verify against the USPTO PatentCenter/PDF copy.
2. Dates: As noted, publication databases differ by one day on priority/filing/grant dates.
3. CAFC 2026: Absence of evidence in my searches is not proof of absence. A definitive check would require a PACER/Docket Alarm or CourtListener query restricted to the Federal Circuit and to 2026, which I could not complete with the search tool available here.
4. "Assignee" vs. "current assignee": Celgene Corporation was the original assignee; Celgene became a Bristol Myers Squibb subsidiary in 2019, so post-2019 filings may name BMS/Celgene.

I'll research litigation involving US 7,968,569. Let me start with searches.

Let me gather more detail on the specific cases identified.

Litigation involving U.S. Patent No. 7,968,569

Important scoping note first. US 7,968,569 B2 ("Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione"; inventor Jerome B. Zeldis; assignee Celgene Corp., now Bristol-Myers Squibb; App. No. 10/438,213; priority 2002-05-17; granted 2011-06-28; Orange Book expiry 2023-10-07) is one member of a large Revlimid® (lenalidomide) patent family. It was never asserted alone — it was asserted as part of a standard seven-patent "bundle" that Celgene used against essentially every lenalidomide ANDA filer. Statements below are limited to matters where I could find the '569 patent specifically identified, and I flag the ones I could not independently verify.

---

1. District court patent infringement actions asserting the '569 patent

All are Celgene Corporation as plaintiff, all in the U.S. District Court for the District of New Jersey unless noted. Plaintiff after November 20, 2019 was effectively Celgene/Bristol-Myers Squibb.

Outcome/status pattern: No case went to judgment on the '569 patent. Celgene/BMS settled with essentially all filers on essentially the same terms as the Natco and Dr. Reddy's deals — a volume-limited generic license beginning around March–September 2022, escalating to unrestricted volume from January 31, 2026. Those settlements (including the '569 patent's claims) are the subject of the antitrust litigation described in §3. The patent itself expired October 7, 2023 (the Google Patents legal status shows "Expired – Lifetime"), so no further infringement actions are possible.

---

2. PTAB proceeding

• IPR2018-01714, Alvogen Pine Brook LLC et al. v. Celgene Corporation — filed September 12, 2018 (Patent Trial and Appeal Board; U.S. Patent No. 7,968,569; application 10/438,213).
  • Outcome: Institution DENIED on March 14, 2019. Google Patents' litigation panel labels it "Not Instituted – Merits"; the PTAB record shows the petitioner's December 11, 2019 request for refund of post‑institution fees and a December 17, 2019 refund notice, consistent with no institution. (A Taiwanese government/industry report likewise states the PTAB rejected the Lotus/Alvogen challenge to the '569 patent on 2019-03-14.)
  • Related: an Indian generics manufacturer (reported as Dr. Reddy's) also petitioned against three Revlimid patents expiring in 2023 — the '569 patent among that group — and the USPTO declined to institute. Case numbers not confirmed in the sources I retrieved.

---

3. Related antitrust / "sham litigation" and pay-for-delay matters citing the '569 patent

The '569 patent is named in the antitrust complaints challenging the Revlimid generic settlements:

• In re Revlimid & Thalomid Purchaser Antitrust Litigation, D.N.J. (lead case 2:19-cv-07532) — along with Humana Inc. v. Celgene Corporation, D.N.J. 2:19-cv-07532 (filed 2019-02-28; Judge Esther Salas). Patents cited include 7,465,800; 7,855,217; 7,968,569; 8,315,886; 8,404,717; 8,530,498; 8,648,095; 9,056,120; 9,101,621; 9,101,622.
• CenterWell Pharmacy, Inc. v. Celgene Corporation, S.D.N.Y. 1:24-cv-06924 (filed 2024-09-13; Judge Edgardo Ramos) — antitrust; patents cited include 7,968,569.
• The Cigna Group v. Celgene Corporation and Blue Cross Blue Shield Association plaintiffs v. Celgene/BMS (D.N.J. and related filings) — same patent set.
• Status as of the most recent reporting: on September 29, 2026, Judge Michael E. Farbiarz (D.N.J.) denied motions to dismiss the antitrust claims, finding a plausible pay-for-delay agreement between Celgene and Natco concerning generic Revlimid (MLex). Earlier rulings (e.g., BMS/Blue Cross decision) dismissed some Walker Process fraud claims.

---

4. Caveats you should carry into any opinion

1. No court ever adjudicated the '569 patent's validity, enforceability, or infringement. Every district court matter ended in settlement or dismissal; the only PTAB challenge was denied institution.
2. Several case numbers in Unified Patents' litigation panel for this patent (2:18-cv-08964, 2:19-cv-15449, and the Par case 2:17-cv-03159) I could not tie to verified party names or confirmed patent-in-suit lists. Do not rely on those rows without pulling the complaints.
3. Unified Patents' panel is drawn from a family-level dataset (Darts-IP family 32314544), so a few listed matters may involve sibling patents in the same family rather than the '569 patent itself.
4. The reissue USRE48890E1 (granted 2022-01-11, "…after stem cell transplantation") sits in the same priority family; check it separately if your question concerns post-2021 assertions.
5. The '569 patent's Orange Book use code is U‑1216, tied to the multiple-myeloma indication claimed in the patent.

If you need PACER docket-level detail (final judgment/consent-judgment entries, dismissal dates, or the exact patents pleaded in the unverified cases above), say which case numbers and I'll pull the specific dockets.

I'll research the AIA trial proceedings on this patent, starting with the one IPR I know of from the patent page.

I have the core IPR record. Let me verify claim 13's text and check for any second proceeding or appeal.

Let me pin down the Board's actual reasoning and confirm no other proceedings exist.

AIA Trial Proceedings — US 7,968,569

⚠️ Data-source discrepancy (flagging explicitly, per operating rules)

The structured "PTAB proceedings on file" block — sourced from the USPTO Open Data Portal — states there are no AIA trial proceedings for this patent. That block is incomplete. Both the patent's own Google Patents page (which lists "PTAB case IPR2018-01714 filed (Not Instituted - Merits)") and the public PTAB record confirm one AIA proceeding. I am treating IPR2018-01714 as real and canonical, and flagging the ODP gap rather than following a default of "no PTAB activity." The ODP's AIA-trial ingest appears not to reach proceedings that terminated at the institution stage in 2019. (My cross-check for any additional proceedings was cut off by a tool-step limit — so I can confirm the presence of IPR2018-01714 with high confidence and cannot rule out a second filing with the same confidence.)

---

Proceedings overview

One AIA trial proceeding exists on US 7,968,569 — IPR2018-01714 (Alvogen v. Celgene) — and it terminated with institution denied on 2019-03-14; zero claims were canceled, zero claims were adjudicated on the merits, there was no Final Written Decision, and there is no appeal. Bottom line for a defendant: the patent's entire claim set (1–15) is UNTESTED at the PTAB — the defensive posture is not "claims are dead," it is "nobody has ever gotten this patent into a trial, and the single petitioner that tried failed at the § 314(a) threshold." Critically for a defendant today, no § 315(e)(2) estoppel attached, because estoppel requires a Final Written Decision.

---

IPR2018-01714 — Alvogen Pine Brook LLC v. Celgene Corp.

• Type: Inter Partes Review
• Filed: 2018-09-12 (Petition accorded filing date 2018-09-18)
• Status: Institution Denied (Google Patents labels it "Not Instituted - Merits") — i.e., the petition was denied on the substantive merits at the § 314(a) threshold, not terminated by settlement
• Judge panel: Grace Karaffa Obermann (opinion author), Tina E. Hulse, Christopher G. Paulraj
• Petition grounds: Challenged claims 1–15 (all claims) on two grounds, both § 103(a) obviousness — no § 102 anticipation and no § 112 grounds were asserted.
  • Ground 1: Palumbo + Celgene's May 2001 press release + Celgene's August 2001 press release
  • Ground 2: Palumbo + Hideshima + U.S. Pat. No. 6,281,230 (the '230 patent)
  • Petitioner's expert: Dr. Guido Tricot. Petitioner also argued the claims were not entitled to the 2002-05-17 provisional priority (contending the effective date was no earlier than 2002-11-06, because the '842 provisional allegedly lacked 28-day-cycle and lenalidomide+dexamethasone disclosure).
• Institution decision: Denied, 2019-03-14, under the § 314(a) "reasonable likelihood" standard. The Board found Petitioner failed to establish that the claimed methods would have been obvious, because the asserted references did not teach or suggest the claimed cyclic dosing (21 days on / 7 days off, 28-day cycle) in combination with dexamethasone. As Jones Day (Celgene's counsel) summarized the ruling: "the PTAB denied institution … finding that Alvogen had not shown a reasonable likelihood of prevailing in its unpatentability challenges because it failed to establish that the claimed methods would have been obvious at the time of the invention." I could not retrieve the full decision text; the analysis above rests on the decision's published sections and Celgene's own description.
• A separate discretionary track was briefed but I cannot confirm it was reached: Celgene's Preliminary Response (2018-12-18) pressed two independent § 314(a) discretionary-denial theories — (i) five advanced, co-pending D.N.J. Hatch-Waxman cases made institution inefficient (citing Mylan v. Bayer, IPR2018-01143), and (ii) IPR of an Orange Book patent would upset the Hatch-Waxman balance. It also raised a real-party-in-interest argument that Dr. Reddy's was an undisclosed RPI. Flagging honestly: I have not verified whether the panel's denial rested on the merits alone, on discretion alone, or both. The public record I could retrieve (including Jones Day's characterization) points to a merits-based denial. Do not cite this as a Fintiv-style discretionary denial without pulling the PDF.
• Final Written Decision: None. No claim was canceled, confirmed, or adjudicated. This is the single most important fact for a defendant — claims 1–15 have never been construed or tested by the Board.
• Settlement / termination: No settlement. The proceeding simply ended at the institution stage. Two follow-on fee events corroborate the clean termination: Respondent's Request for Refund of Post-Institution Fees (2019-12-11, $15,000) and the Board's Notice of Refund (2019-12-17) granting it. A refund of post-institution fees is only issued when trial never starts.
• Appeal: None, and none is legally available on the merits. Because institution was denied, 35 U.S.C. § 314(d) bars direct appeal (the "No Appeal" / non-reviewability principle confirmed in Cuozzo and Mylan Pharmaceuticals v. Janssen, 989 F.3d 1379 (Fed. Cir. 2021) — mandamus is theoretically available but effectively unobtainable for institution denials). I found no Alvogen mandamus petition or any Federal Circuit docket arising from IPR2018-01714.
• Counsel: Petitioner — Baker Botts (Stephen M. Hash, lead). Patent Owner — Quinn Emanuel (F. Dominic Cerrito, Frank C. Calvosa) and Jones Day (Anthony M. Insogna) plus Celgene in-house (J. Patrick Elsevier).
• Defensive value: Mixed, and time-sensitive. On the plus side for a defendant, Alvogen did assemble a facially serious § 103 case and the Board never blessed the claims as valid — the surviving "validity" signal is only a threshold-likelihood finding, not a merits adjudication, and it carries no estoppel effect on anyone. On the minus side, the Board's reasoning — that Palumbo (thalidomide) and Hideshima are silent on any 7-day rest period, and that the art if anything pointed to longer (2-week-plus) rest intervals — is a warning that the 21+7 limitation is the hard nut. Any new IPR must clear a higher bar by showing the specific 21+7 cycle, not just lenalidomide+dexamethasone. But note the patent expired 2023-10-07, so a fresh IPR would likely be denied as moot/for the wrong reasons — see below.

---

Strategic summary

Claim status: everything is UNTESTED. Claims 1 and 13 are the only independent claims; the Board confirmed "Claims 1 and 13 are the only independent claims," with the remaining claims inheriting the 21+7 regimen by dependence (claims 2–12 from claim 1; claims 14–15 from claim 13). Because IPR2018-01714 ended at institution, no claim of the '569 patent has been canceled, confirmed, or construed by the PTAB. There is no "surviving claim" list to report — the full set 1–15 remains as issued (as corrected by the 2012 Certificate of Correction referenced at col. 32). Do not tell a defendant that any claim is dead; that would be wrong. Anyone asserting the '569 patent today holds a fully intact, never-invalidated claim set.

Estoppel: none, on anyone. Section 315(e)(2) estoppel is triggered only by a Final Written Decision. There was none, so Alvogen (and its privies) are NOT estopped from raising in district court the very Palumbo/Hideshima/press-release § 103 grounds it lost at the institution stage — and, symmetrically, Celgene obtained no estoppel benefit. This is a material contrast with the MDS patents: three Dr. Reddy's IPRs were likewise denied institution on 2019-02-11 (on a public-availability evidentiary defect, per the Revlimid antitrust complaint), and DRL then cured that defect in district court with sworn affidavits. That dynamic — institution denial for evidentiary reasons, followed by district-court success on the same art — is the live risk profile for the '569 patent as well.

Pattern signals. (1) Single petitioner; no repeated filer on this patent. Alvogen filed once; Dr. Reddy's deliberately did not petition on the '569 patent (it filed on the MDS patents instead), a split-and-conquer strategy Celgene called out in its Preliminary Response. (2) No defensive aggregator in the chain. The "Unified Patents" attribution on the Google Patents page is a data-source credit — the petitioner is Alvogen, not Unified. I found no Unified Patents IPR against the '569 patent. (3) Patent owner never had to defend at trial, so Celgene never pursued a PTAB appeal. (4) The '569 patent's PTAB history is now being litigated as evidence in the Revlimid antitrust action (D.N.J.), where plaintiffs argue Celgene settled the Natco case to avoid an invalidity ruling on the dosing-regimen claims.

The expiration problem dominates everything. The patent expired 2023-10-07 (Orange Book use code U-1984, NDA 021880). A defendant facing a new assertion would be litigating past damages only. More importantly, expiration makes a new IPR a poor vehicle: the Board has been increasingly willing to deny institution on patents close to or past expiry, and post-expiration the practical value of cancellation is low. If you are defending an ongoing case that accrued pre-expiration damages, the better play is a district-court § 103 attack on the 21+7 cycle (where Alvogen's art is not estopped), not a new PTAB petition.

---

Recommended next steps

1. Verify the ODP gap and get the primary documents. The canonical ODP block is missing IPR2018-01714 — corroborate against the PTAB E2E portal and the decision PDF itself:

   • Institution Decision (2019-03-14): https://www.docketalarm.com/cases/PTAB/IPR2018-01714/Inter_Partes_Review_of_U.S._Pat._7968569/docs/03-14-2019-Board/Institution_Decision-7-Trial_Instituted_Document.pdf
   • Petition and Patent Owner Preliminary Response via USPTO PTACTS petition record 1518596: https://ptacts.uspto.gov/ptacts/public-informations/petitions/1518596/download-documents
   • Notice of Refund (2019-12-17): https://www.docketalarm.com/cases/PTAB/IPR2018-01714/Inter_Partes_Review_of_U.S._Pat._7968569/docs/12-17-2019-Board/Refund_Approval-9-Notice_of_Refund.pdf

2. Pull the full institution decision and read the dispositional sentence verbatim before relying on the "merits vs. discretion" characterization. My analysis rests on secondary description (including Celgene's counsel's summary at https://www.jonesday.com/en/practices/experience/2019/03/celgene-successfully-blocks-ptab-institution-of-ip). The distinction matters: a merits denial tells you the 21+7 limitation is the battleground; a discretionary denial tells you nothing about validity.

3. Confirm the absence of a second proceeding. I could identify only IPR2018-01714. Run a targeted PACER/PTAB-E2E and CourtListener query restricted to the '569 patent and to 2019–2026 to rule out a follow-on Alvogen, DRL, or aggregator petition, and a Federal Circuit query for any mandamus attempt (none found).

4. Do not build an estoppel or collateral-estoppel argument on this record. There is no FWD and no claim-level holding. The only portable findings are the Board's preliminary, non-binding observations that Palumbo/Hideshima are silent on a 7-day rest period and that the art pointed toward longer rest intervals — useful as persuasive district-court material, but not issue-preclusive.

I'll research the assignment record for this patent. Let me run several searches in parallel.

Good — I have a key data point (Reel 014517/0556). Let me verify and look for any post-issuance or post-merger records.

Ownership Reconstruction — US 7,968,569 B2

Scope note / data limitation (read first): I was able to confirm one recorded assignment for this patent from a primary-quoted source (Celgene's own PTAB mandatory notice, which cites the reel/frame). I could not run a live query against the USPTO Assignment Center API from this environment, so I could not enumerate the full recording history myself, and in particular I could not retrieve the "correspondent of record" field for any entry. Where I lack a value I say so rather than infer it. Google Patents' legal-events feed for this patent shows only the single inventor-to-employer assignment below — no post-issuance transfer is listed.

---

Inventors

Pattern notes:

• Not unusual. A single inventor who is a senior executive of the assignee company, assigning to that company, is the ordinary "employee invention" pattern for pharma method-of-use cases. Zen: Joel. There is no evidence of inventors departing within 12 months of filing, no inventor-hired-by-NPE pattern, and no co-inventor fragmentation.
• Zeldis is a prolific named inventor across the Celgene IMiD portfolio (he appears as inventor on sibling patents such as US 9,050,324, US 8,530,498, etc.), consistent with an in-house executive-inventor rather than a hired "patent-factory" inventor.
• Caveat: I did not independently verify Zeldis's employment-contract IP-assignment obligation or his exact title as of May 2003; the "VP/CMO" characterization comes from later court filings describing him, and is consistent but not dated precisely to the filing.

---

Original assignee

• Entity on the issued patent: Celgene Corporation, a Delaware corporation, principal place of business 86 Morris Avenue, Summit, New Jersey 07901 (as stated in Celgene's own PTAB mandatory notice for the '569 patent). At the 2003 filing, Celgene's address of record in USPTO recordings was 7 Powder Horn Drive, Warren, NJ 07059 (this address appears on contemporaneous 2003 Celgene recordings in the same portfolio — flagged as contextual, taken from a sibling record, not the '569 record itself).
• Product embodying the claims: Yes — REVLIMID® (lenalidomide). The '569 patent was listed in the FDA Orange Book for NDA 021880 (REVLIMID), use code U-1216 (later U-1984), expiring 2023-10-07. The claimed subject matter is lenalidomide 5–25 mg/day on a 21-on/7-off 28-day cycle with dexamethasone for multiple myeloma — exactly the approved Revlimid MM regimen.
• Primary line of business: Commercial-stage biopharmaceutical company (oncology / immune-inflammatory), with Revlimid and Thalomid as its principal products in the relevant era.
• Current status: Operating, but no longer independent. Celgene was acquired by Bristol-Myers Squibb in a cash-and-stock merger announced 2019-01-03 and closed 2019-11-20, at which point Celgene became a wholly owned subsidiary of BMS. Celgene common stock ceased trading 2019-11-20. The Celgene legal entity was not dissolved and was not in bankruptcy. No Chapter 7/11 proceeding is relevant here.
• Key structural point: Because the BMS transaction was a stock merger (Celgene survived as a wholly owned subsidiary), legal title to the '569 patent did not need to move by assignment. That is why the assignment record stops at 2003 and why the BMS acquisition does not appear as a reel/frame on this patent. This is a positive finding about the record, not a gap.

---

Assignment timeline

Chronological record of what is actually documented:

• Executed: not established from accessible sources / recorded 2003-09-15 — Reel 014517 / 0556
  • Conveyance: Assignment (assignment of assignors' interest — inventor to employer)
  • Assignor: Jerome B. Zeldis (sole inventor)
  • Assignee: Celgene Corporation
  • Correspondent: Not retrievable from the sources I could access. This is the field the task specifically asked me to capture, and I could not obtain it. I will not guess at an attorney or firm name. (See signal 3 below — this makes the repeat-correspondent test not assessable on present evidence.)
  • Context: Routine inventor-to-employer assignment executed in connection with the original filing; the ordinary "employment invention" link that perfects the assignee's record title. Not a fire-sale, not a securitization, not a transfer to an asserter.
  • Source of the reel/frame: Celgene's Patent Owner Mandatory Notices in IPR2018-01714 (P.T.A.B., filed 2018-10-03), which state verbatim that Celgene "is the owner of all right, title, and interest in U.S. Patent No. 7,968,569 … by virtue of an assignment from the inventor, Jerome B. Zeldis. The Assignment was recorded on September 15, 2003 at Reel 014517, Frame 0556."

No other assignment records are evidenced. In particular:

• No post-issuance assignment (2011 or later) appears.
• No security agreement / collateral mortgage against this patent was found in my searches. I could not rule one out — Celgene was a serial issuer of convertible notes and maintained credit facilities, and lender collateral recordings against patent portfolios are common. Treat this as "not found," not "confirmed absent."
• No reissue assignment. Note the family confusion risk: US RE48,890 E1 (application 16/283,631, filed 2019-02-22) is titled "…after stem cell transplantation" and appears to belong to the stem-cell-transplant MM patent ('621 family), not to the '569 patent. It is a sibling patent family (shared 2002-05-17 / 2002-11-06 priority), and should not be read as a reissue of '569. (Flagged because the family tables circulating online interleave these.)
• Divisional/continuation line does not change '569 title: the '569 application (10/438,213) is itself the parent; children such as 12/229,074 → US 8,198,262 and later continuations (e.g., US 9,050,324) are separate patents with their own records.

If you need the correspondent field (the whole point of the exercise), pull the reel/frame 014517/0556 image directly from USPTO Patent Assignment Search: https://assignment.uspto.gov/patent/index.html (search "7968569" or reel 014517 frame 0556), or the newer https://assignmentcenter.uspto.gov/. That single document will give you the attorney/agent of record for the 2003 recording.

---

Timeline diagram

timeline
    title Ownership of US 7968569
    2002 : Priority provisionals filed
    2003 : Non-provisional filed by Zeldis
         : Assigned to Celgene Corp
    2010 : Celgene sues Natco
    2011 : Patent issued
    2017 : Celgene sues Lotus Alvogen
    2018 : IPR filed by Alvogen
    2019 : IPR institution denied
         : Celgene acquired by BMS
    2023 : Patent expired

(Events are year-stacked with leading colons; text kept short and free of parentheses, slashes, and commas.)

---

NPE / troll-pattern signals

---

Verdict

Operating-company assertion.

The chain consists of a single documented link — the 2003-09-15 inventor-to-employer assignment from Jerome B. Zeldis to Celgene Corporation at Reel 014517/Frame 0556 (per Celgene's own PTAB mandatory notice) — after which Celgene, a commercial-stage biopharma that actually shipped the claimed product (REVLIMID, Orange Book use code U-1216/U-1984, expiring 2023-10-07), sued generic ANDA filers directly in its own name (Natco, 2010; Lotus/Alvogen, 2017–18). No LLC, assertion vehicle, or defensive aggregator ever appears in the chain, and the BMS acquisition transferred ownership economically and structurally by stock merger rather than by any recorded patent assignment, which is why the record properly ends in 2003. No NPE/troll signal is present; the one open item is that I could not read the correspondent field on Reel 014517/0556, so signal 3 is untested rather than negative.

Verify: https://assignment.uspto.gov/patent/index.html (search patent 7,968,569 / reel 014517 frame 0556) · https://assignmentcenter.uspto.gov/ · cross-check legal events at https://patents.google.com/patent/[US7968569B2](/patent/US7968569B2)/en

I'll research the prior-art citations for US 7,968,569. Let me run several targeted searches.

Let me pull the front-page references and the IPR record, which identifies the actual prior art asserted.

Excellent — the IPR petition identifies the real prior-art set. Let me pin down the exhibit list, grounds, and the front-page cited references.

Prior-Art Analysis — US 7,968,569 B2

0. Target-document verification (anchor first, then cite)

I anchored exclusively on US 7,968,569 / application 10/438,213. I did not find results for lookalike numbers being conflated (e.g., 7,968,569 vs. its own family members 7,468,363, 7,393,862, 8,198,262, 8,648,095, 8,632,787 and the sibling application 10/704,237) — those are same-family members, not prior art, and I exclude them from the prior-art tables below.

Charge to the reader: the Google Patents OCR text supplied to me is truncated before the printed claim set and before the "References Cited" block. Everything below that concerns claim language is taken from the IPR2018-01714 record (petition, Tricot declaration, and the Board's 14 March 2019 denial decision), which quotes the claims verbatim. Where I could not verify a date or title, I say so rather than invent one.

---

1. What the claims actually require (from the IPR record)

Claims 1–15 were challenged in IPR2018-01714. From the record:

• Claim 1 — method of treating multiple myeloma by cyclically administering, in combination with 40 mg/day dexamethasone: ~5–25 mg/day of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (= lenalidomide) "for 21 consecutive days followed by seven consecutive days of rest from administration of said compound during a 28 day cycle."
• Claim 13 — independent claim with the same 21 + 7 lenalidomide cycling, plus a specified dexamethasone schedule.
• Claims 2, 4, 5, 6, 7–12, 14 — depend (directly/indirectly) from claim 1 (e.g., 7 = 10–25 mg/day; 8 = about 5, 10, 20 or 25 mg/day; 10 = 5 mg/day; 11 = 10 mg/day; 12 = capsule of 5/10/15/25 mg; 14 = capsule with lactose anhydrous, MCC, croscarmellose sodium, magnesium stearate).
• Claim 15 — depends from claim 13.

The critical technical fact for §102 purposes: the Board found that "none of the five references identified in the asserted grounds … teaches or suggests cyclic dosing of any agent — let alone the compound that was later known as lenalidomide — for 21 consecutive days followed by a 7-day rest period. None of the five references mentions a rest period of any duration." (Institution Decision, IPR2018-01714, Paper 7.)

---

2. The two distinct prior-art universes for this patent

It is important not to blend these, because they answer different questions:

• Universe A — the patent's own citation apparatus: the U.S. patents, foreign documents and NPL listed on the face of the patent / cited in the specification. These are the background art: they establish that lenalidomide, α-amino isoindolines, thalidomide anti-angiogenesis, GM-CSF/G-CSF, and osmotic/transdermal dosage technology were known.
• Universe B — the art actually asserted against the claims: the five references (plus secondary references) in Alvogen Pine Brook LLC's IPR petition. These are the invalidity art, and — importantly — they were asserted only under §103, never under §102.

---

3. Universe A — references cited by/against the '569 disclosure

⚠️ Caveat: I could not retrieve the complete printed front-page "References Cited" list. The items below are drawn from (i) the specification text I was given, (ii) the Unified Patents "Patent Art (101)" mapping for US-7,968,569, and (iii) the PubChem patent record for US-7968569-B2. Treat this as a well-supported reconstruction, not a verbatim front page.

---

4. Universe B — the art actually asserted (IPR2018-01714, Alvogen Pine Brook LLC v. Celgene Corp.)

The petition asserted two grounds, both §103(a) — no §102 ground was pleaded at all:

• Ground 1: Palumbo + the May Press Release + the August Press Release
• Ground 2: Palumbo + Hideshima + the '230 patent

---

5. §102 verdict — explicit and unhedged

No reference identified above anticipates claims 1–15 of US 7,968,569 under 35 U.S.C. § 102, and no §102 ground was ever pleaded. This is not a soft conclusion; it is the express finding of the Board:

"None of the five references mentions a rest period of any duration." — Institution Decision, IPR2018-01714 (14 Mar. 2019), denying institution under §314(a).

Every claim in the patent contains the 21-consecutive-days-on / 7-consecutive-days-off limitation (claims 1 and 13 directly; claims 2–12, 14 and 15 by dependency), and no single reference discloses it. Under §102, a dependent claim inherits all limitations of the claim from which it depends, so the fact that the May Press Release discloses 5/10/25 mg (claims 8, 10, 11) or that Palumbo discloses dexamethasone 40 mg days 1–4 monthly (relevant to claim 13) cannot produce anticipation of any claim.

What the art is actually good for (§103): the invalidity theory is a three-reference obviousness mosaic:

• '230 patent → the compound and the 1–100 mg range
• Hideshima → lenalidomide's direct anti-MM activity and superior potency over thalidomide
• Palumbo + Celgene press releases → MM treatment cycles and the 40 mg dexamethasone schedule

The Board rejected that mosaic as insufficient on the record presented, and I have no basis to second-guess that on the sources available to me. Additional live theory: the Revlimid antitrust plaintiffs' amended complaint (Nov. 2024) alleges Dr. Reddy's had assembled press-release evidence on "safe and effective treatment of MM at the relevant dosing amounts," but expressly notes the MM patents' independent claims "had an additional limitation — … lenalidomide administered on days 1-21 of a 28-day cycle, and thereby incorporating a 7-day rest period." That is a §103 attack too, not §102.

---

6. A separate §102 theory raised in the district court (not §102(a)/(b))

In Celgene v. Lotus / Alvogen, No. 2:17-cv-06842 (D.N.J., Wigenton, J., op. 14 Dec. 2018), and in the Celgene v. Hetero Labs invalidity contentions, defendants pleaded a §102(f)/(g) derivation/prior-invention attack: that the claimed subject matter "was previously invented in this country by another inventor" — Robert D'Amato (and/or D'Amato with The Children's Medical Center Corporation) — and that "the listed inventor, Jerome B. Zeldis, did not invent himself the subject matter claimed." The contentions listed 109 prior-art references under §§102(a), (b), (e), (f), (g) and 18 exemplary combinations. If the user's question is scoped to all §102 theories rather than only §102(a)/(b) documentary art, this is the one non-frivolous one — and it is an inventorship theory, not a documentary-anticipation theory. (Source: ECF No. 723, Ex. C–D, reproduced in the Celgene v. Hetero opinion PDF at carlsoncaspers.com.)

---

7. Contradiction/uncertainty flags (per instruction to flag rather than silently resolve)

1. Claim-text source. The earlier summary correctly noted the Google Patents text is truncated before the claims; I have now cross-checked claim 1 and claim 13 against two independent IPR documents (petition and Tricot declaration) plus the Board's decision, and they agree. Residual uncertainty remains on the exact days-1–4 wording of claim 13's dexamethasone limitation — I could confirm the lenalidomide 21+7 limitation of claim 13 verbatim but not its full dexamethasone sentence.
2. "August Press Release" (Ex. 1013) identity. The Board calls it the "August Press Release"; the petition's OCR table attaches to Ex. 1013 text beginning "Celgene Corporation Awarded Additional Patent…". These are inconsistent. I did not resolve which is correct, and the answer matters: an August 2001 release is §102(a)/(b) art; an August 2002 release post-dates the 2002-05-17 priority and is not prior art.
3. Claim-dependency. Earlier drafting described claim 13 as the independent claim for claims 14+. The IPR record shows claim 14 depends from claim 12 (hence from claim 1), and only claim 15 depends from claim 13. Corrected here.
4. Front-page references. I could not retrieve the printed "References Cited" block. Universe A is a reconstruction from the specification text, the Unified Patents art map, and the PubChem record. The exact U.S./foreign patent list on the '569 front page should be confirmed against the USPTO PatentCenter PDF before being quoted as a face-of-patent citation.
5. Post-priority items mistakenly appearing as "cited references." Richardson et al. Blood 2005 and the 2003/2004 Celgene press releases are not prior art to the '569 claims; they appear because reference lists are aggregated across the family/IDS history.

---

8. Sources used

• US 7,968,569 B2 full text — https://patents.google.com/patent/[US7968569B2](/patent/US7968569B2)/en
• Institution Decision, IPR2018-01714, Alvogen Pine Brook LLC v. Celgene Corp. (14 Mar. 2019) — https://www.docketalarm.com/cases/[PTAB](/ptab)/IPR2018-01714/Inter_Partes_Review_of_U.S._Pat._7968569/docs/03-14-2019-Board/Institution_Decision-7-Trial_Instituted_Document.pdf
• Petition for IPR of claims 1–15 of US 7,968,569 (12 Sep. 2018) — https://www.docketalarm.com/cases/PTAB/IPR2018-01714/Inter_Partes_Review_of_U.S._Pat._7968569/docs/09-12-2018-Petitioner/Petition-1-Petition_for_Inter_Partes_Review_of_US_Patent_No_7,968,569.pdf
• Declaration of Dr. Guido Tricot in support of the petition — https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1518596](/patent/1518596)/download-documents (Exhibit filed 2018-09-12)
• Patent Owner Preliminary Response, IPR2018-01714 (18 Dec. 2018) — https://gaeflexstaging-dot-docketupdate.appspot.com/cases/PTAB/IPR2018-01714/...
• Declaration of James L. Mullins, PhD (Ex. 1055), authenticating Palumbo — https://gaeflexstaging-dot-docketupdate.appspot.com/cases/PTAB/IPR2018-01714/...
• Unified Patents patent page for US-7968569-B2 — https://portal.unifiedpatents.com/patents/patent/7968569
• PubChem patent record US-7968569-B2 — https://pubchem.ncbi.nlm.nih.gov/patent/US-7968569-B2
• Celgene Corp. v. Lotus Pharmaceutical Co., Ltd. / Alvogen Pine Brook, LLC, No. 17-6842 (D.N.J. 14 Dec. 2018) — https://cases.justia.com/federal/district-courts/new-jersey/njdce/2:2017cv06842/[354127](/patent/354127)/90/0.pdf
• Celgene Corp. v. Hetero Labs Ltd. (D.N.J.) invalidity-contentions opinion — https://www.carlsoncaspers.com/wp-content/uploads/2021/07/Celgene-Corp.-v.-Hetero-Labs-Ltd..pdf
• Revlimid antitrust amended complaint (5 Nov. 2024) — https://www.hbsslaw.com/sites/default/files/case-downloads/revlimid/2024-11-05-corrected-amended-complaint-redacted.pdf
• Taiwanese IPO disclosure materials on the Lotus/Alvogen IPR — https://www1.tipo.gov.tw/tw/dl-[287732](/patent/287732)-d05ed916c6074a6b947bd0154233b51e.html

I'll research the prior art landscape for this patent before analyzing.

Let me get more detail on the specific grounds and the press-release prior art.

Let me pull the PTAB's reasoning in denying institution, plus check for any later district-court validity outcome.

Obviousness Analysis — US 7,968,569 B2 under 35 U.S.C. § 103

Analyst note on scope of this section. This analysis builds on the previously generated summary (which I treat as authoritative for the bibliographic data and claim identification) and does not repeat it. Two corrections to that earlier section are flagged in §IX below. The "Prior Art" material available on the patent page itself is thin — it consists of the indexed prior-art keywords ("patients, administered, compound, cancer, immunomodulatory compound"), the chemical structures indexed against the description, and the references cited in the specification (U.S. Pat. Nos. 5,635,517; 5,874,448; 5,929,117; 6,281,230; 6,316,471; 4,810,643; 4,999,291; 5,391,485; 5,393,870; 5,229,496; 5,528,823; 5,580,755). Because that is a specification-reference list rather than an examiner's citation list, I have supplemented it with the actual prior-art record developed in the one post-grant challenge to this patent, Alvogen Pine Brook LLC v. Celgene Corp., IPR2018-01714, whose petition, preliminary response, and 14 March 2019 institution decision I located and cite below.

---

I. Legal framework and the correct burden

The claims are method-of-use claims subject to § 103(a). The controlling framework is Graham v. John Deere, 383 U.S. 1 (1966) (scope/content of prior art; differences; PHOSITA level; secondary considerations), as refined by KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007) (a "combination of familiar elements according to known methods is likely to be obvious when it does no more than yield predictable results"; express teaching, suggestion, or motivation is not required). A patent may be obvious if the combination was "obvious to try" or if a known problem had an obvious solution within the claims. KSR, 550 U.S. at 421.

A PHOSITA here is an M.D./Ph.D.-level clinician-scientist in hematology/oncology with experience designing and running Phase I/II myeloma trials and familiarity with the thalidomide/IMiD literature. The parties in IPR2018-01714 stipulated to, and did not contest, this level of skill.

I analyze the two independent claims and their dependents under the two grounds actually pleaded, then under alternative combinations the record supports.

---

II. The claimed subject matter (from the record, not the page's truncated text)

The Google Patents page supplied to us is truncated before the claims. The Board reproduced claim 1 verbatim in its institution decision, and I rely on that:

Claim 1: "A method of treating multiple myeloma, which comprises cyclically administering to a patient having multiple myeloma about 5 to about 25 mg per day of a compound of the formula [lenalidomide] or a pharmaceutically acceptable salt thereof, for 21 consecutive days followed by seven consecutive days of rest from administration of said compound during a 28 day cycle, in combination with 40 mg per day of dexamethasone."

Claim 13: Same 21+7 regimen, but "about 25 mg per day" of lenalidomide and 40 mg per day of dexamethasone "on days 1-4 every 28 days."

Dependents 2–12 and 14–15 all inherit the "21+7" limitation (Pet. at 303–415; Paper 7 at 6). Claims 7–12 recite dose amounts (10–25 mg/day; about 5, 10, 20 or 25 mg/day; 25 mg/day; 5 mg/day; 10 mg/day) and a capsule of 5/10/15/25 mg; claim 14 recites a capsule containing lactose anhydrous, microcrystalline cellulose, croscarmellose and magnesium stearate.

Critical claim-construction observation: claim 1 does not specify when the 40 mg dexamethasone is given. Read literally, it requires only that 40 mg/day of dexamethasone be co-administered during the cycle. That reading materially enlarges the prior-art coverage of claim 1, as shown in §IV.A.3.

Three limitations therefore do the inventive work: (a) substituting lenalidomide for thalidomide; (b) the 5–25 mg/day or 25 mg/day dose; (c) the 21-on/7-off schedule.

---

III. The prior-art references

III.A. Compound and genus disclosures (from the patent's own specification's reference list)

Taken together, these establish that the molecule claimed in structural form in claim 1 was known before the priority date, and that the '230 patent already claimed the combination of lenalidomide (1–100 mg) with a steroid such as dexamethasone for cancer. This is the single most important piece of prior art against the "substitution" limitation.

III.B. Multiple-myeloma efficacy of the compound class

III.C. Thalidomide + dexamethasone in MM, and the dexamethasone schedule

Note on the 40 mg dexamethasone figure: 40 mg/day dexamethasone, administered as short pulses within a 28-day cycle, was the entrenched MM standard of care and is precisely what Palumbo used. Claim 13's "days 1–4 every 28 days" is a literal subset of Palumbo's days 1–4 / 9–12 / 17–20 schedule.

---

IV. Ground 1 — Palumbo + May Press Release + August Press Release

This was Petitioner's primary ground in IPR2018-01714. Element-by-element:

Ground 1's strength: every limitation except the 21+7 rest period is expressly disclosed or obvious. The gap is narrow and quantitative.

---

V. Ground 2 — Palumbo + Hideshima + '230 Patent

Petitioner's secondary ground. The motivation chain is stronger here:

1. Hideshima shows that the IMiD class (including lenalidomide) is more potent than thalidomide against MM cells in vitro and that dexamethasone is additive/supra-additive with the IMiDs (Ex. 1016, Fig. 3).
2. Palumbo expressly cites Hideshima as the rationale for pairing thalidomide with dexamethasone and states the two drugs are "a logical combination."
3. The '230 patent claims a method of treating cancer by administering 1–100 mg of lenalidomide in combination with a steroid such as dexamethasone (Ex. 1028). The claimed 5–25 mg/day and 25 mg/day doses fall squarely inside the '230 range.

Thus the concept of "lenalidomide + dexamethasone for cancer (including MM)" is not merely suggested by Ground 2 — it is claimed in an earlier patent in the same family. This is the classic KSR "predictable variation" scenario: the only things left to a PHOSITA are (a) picking the dose within the already-disclosed 1–100 mg range (and within the 5–25 mg range shown tolerable in the May Press Release), and (b) choosing a schedule.

---

VI. Alternative and additional combinations

Even setting Grounds 1–2 aside, several other combinations are available on this record:

Combination A: '230 patent + Palumbo. The '230 patent supplies "lenalidomide 1–100 mg + a steroid such as dexamethasone for cancer"; Palumbo supplies the MM indication, the 28-day cycle, and the 40 mg/day pulsed dexamethasone schedule. Combining them yields claims 1 and 13 almost mechanically, with the sole residual question being the 21+7 rest.

Combination B: May Press Release + Singhal + Hideshima. Singhal establishes that thalidomide (the parent compound) works in refractory MM; Hideshima establishes that lenalidomide is a more potent MM-active analog; the May Press Release establishes the human 5/10/25 mg dose cohorts and tolerability. The substitution of one for the other is a one-way, predictable escalation.

Combination C: any of the above + DeVita / general cycling practice. The '569 specification itself states the rationale for cycling: a rest period "can reduce the development of resistance … avoid or reduce the side effects … and/or improve the efficacy of the treatment" ('569 spec. 24:20–28). That statement is an admission of what the art already understood about cyclical chemotherapy. Because the May Press Release and the December 2001 press release both disclose that lenalidomide produced granulocyte and platelet reductions at higher doses in the extension phase (Ex. 1012; Ex. 1014), a PHOSITA had a concrete, art-recognized reason to build a rest period into a lenalidomide regimen — myelosuppression is the textbook indication for a drug holiday. See Ex. 2012 (M.S. Gordon, Myelosuppression, Current Cancer Therapeutics (4th ed. 2001)) — a reference Celgene itself put in the record.

---

VII. Motivation to combine — the affirmative case

A PHOSITA would have had at least five independent motivations to arrive at the claimed methods:

1. Same field, same problem. Every reference addresses treatment of multiple myeloma (or the general oncology use of the same compound class). There is no field-boundary problem: all are analogous art, and the KSR "interrelated teachings" standard is easily met.
2. Express lead-compound teaching. The May 2001 press release tells the world that REVIMID is Celgene's "lead IMiD for the treatment of multiple myeloma" and was being studied at exactly 5, 10 and 25 mg/day. A PHOSITA would not need to guess that lenalidomide was the compound to try.
3. Express combination teaching. Hideshima (Fig. 3) and Rajkumar (at 3594) both report that dexamethasone adds to or synergizes with IMiDs/thalidomide against MM. Palumbo applied that teaching clinically with thalidomide and dexamethasone in a 28-day cycle and reported efficacy.
4. Prior-patent teaching. The '230 patent (Celgene's own) claims lenalidomide 1–100 mg plus a steroid such as dexamethasone for cancer. A PHOSITA seeking a lenalidomide-based MM regimen would have been directed, not merely permitted, to combine.
5. Dose optimization is routine. Selecting 5–25 mg/day from the disclosed 5/10/25/50 mg cohorts — and specifically 25 mg/day in claim 13 — is the paradigm of a "result-effective variable" optimized by routine experimentation, particularly where the May Press Release expressly identifies 25 mg/day as the top of the "well tolerated" range with the strongest responses ("All three patients at the highest dose level (50 mg/day) were responding"; "Improved response was seen with higher dosages of REVIMID").

The 28-day cycle is also not an inventive selection: it is the cycle length Palumbo used for the dexamethasone pulses and the standard MM cycle length.

---

VIII. The rebuttal case — and why this is genuinely close

I would be doing the analysis a disservice to present only the affirmative side. Celgene's preliminary response (Paper 6, IPR2018-01714) made four arguments that the Board found sufficient to deny institution:

1. No reference discloses the 21+7 rest period. This is correct as a matter of express disclosure. The May Press Release describes continuous daily dosing for 2 or 4 weeks followed by an optional extension; Palumbo describes continuous thalidomide. Neither teaches inserting a 7-day drug holiday at day 22 of a 28-day cycle. Under Orexo AB v. Actavis Elizabeth LLC, 903 F.3d 1265, 1273 (Fed. Cir. 2018) — cited in the record — the question is "whether the prior art suggested the selection and combination achieved by the inventor," not whether the pieces existed separately.
2. Teaching away on rest-period length. Celgene pointed to Petitioner's own DeVita reference (Ex. 1017 at 16), which prescribes a "familiar 2-week interval between cycles," and to MM references using rest periods of three weeks or more. If the art's conventional rest is 14 days, selecting 7 days is arguably a deviation rather than a routine optimization.
3. Myelosuppression counselled caution, not a shorter cycle. Celgene argued that lenalidomide was known to cause "profound cytopenias and significant myelosuppression" and that the prior art would not have motivated a 21-day continuous exposure — the very toxicity that later justified the rest period could, on the prior-art record, as easily have justified a longer rest or lower dose.
4. Alleged unexpected results. The prosecution history (Celgene Ex. 2008, Ex. 2008 File History Excerpt) shows that during the 29 November 2010 examiner interview, counsel distinguished Kyle (Semin. Oncol. 2001), Davies (Blood 2001) and Corral (Ann. Rheum. Dis. 1999) on the ground that they "fail to suggest the claimed methods, which require the use of [lenalidomide] and dexamethasone for treating multiple myeloma in specific amounts and specific dosing regimens," and submitted Gay, Blood 2010;115:1343–1350 as evidence of unexpected results, together with the March 2010 Revlimid® FDA-approval exhibit.

Petitioner's counter to (4) is the Galderma Labs. v. Tolmar, 737 F.3d 731, 739 (Fed. Cir. 2013) point quoted in the record: results that differ from the prior art "merely in degree" rather than "in kind" are not probative of nonobviousness, and the press releases already taught that lenalidomide was "more potent" with "a better safety profile" and was effective in thalidomide-resistant patients. Petitioner also argued that the Gandhi in vitro synergy data was predictable given Hideshima and the thalidomide/dexamethasone synergy literature.

My assessment: The affirmative case is strong on claims 1–12 and 14–15, where the law of routine optimization (In re Aller; In re Boesch) does most of the work — 5–25 mg is disclosed, 40 mg dexamethasone is disclosed, and 28-day cycles are disclosed. The affirmative case is weakest on the 21+7 limitation in isolation, because the record contains a genuine teaching-away datum (14-day rest convention) and because the Board accepted that no reference taught the specific 7-day rest. The strongest overall theory is not a single two- or three-reference ground but a genus-substitution + routine-optimization theory anchored on the '230 patent (lenalidomide 1–100 mg + dexamethasone for cancer) combined with the May Press Release (5–25 mg human tolerability/response data) and Palumbo (28-day cycle with 40 mg/day dexamethasone pulses), with the myelosuppression references (Ex. 2012) supplying the motivation for the rest period and the '569 specification's own cycling rationale (24:20–28) supplying the recognition that cycling was already a known technique. That is a materially different, and stronger, articulation than either of the two grounds actually pleaded.

---

IX. Corrections and caveats relative to the earlier-generated section

1. The IPR petitioner was not Unified Patents. The earlier summary described IPR2018-01714 as a "Unified Patents" proceeding. The record shows the petitioner was Alvogen Pine Brook LLC (Baker Botts LLP as counsel; Stephen M. Hash, Margaret J. Sampson, Jeffrey S. Gritton), against Celgene Corporation (Quinn Emanuel / Jones Day). The Google Patents page lists the petitioner field blank under the Unified Patents data feed, which likely caused the misattribution.
2. The IPR was filed 12 September 2018, not 2017. The "2017" date in the earlier summary corresponds to the Lotus/Alvogen Paragraph IV ANDA notice (24 July 2017) and Celgene's related district court complaint, Celgene v. Lotus Pharm. Co. / Alvogen Pine Brook, No. 2:17-cv-06842 (D.N.J., filed 6 Sept. 2017). The IPR was filed almost a year later, less than a week before the § 315(b) one-year bar — a timing Celgene attacked as tactical. Institution was denied 14 March 2019 on the § 314(a) "reasonable likelihood" threshold, not on a final merits determination.
3. No merits adjudication exists. Because the Board denied institution and the district court actions settled via consent judgments (e.g., the 29 March 2019 Lotus/Alvogen stipulation; the 22 June 2021 Sun consent judgment), the § 103 validity of the '569 patent was never adjudicated on the merits by any tribunal — neither by the PTAB nor by a district court after trial. Any statement that the claims are valid or invalid over this art is a predictive legal opinion, not a finding. The Dr. Reddy's invalidity arguments described in the later antitrust complaint (opening/reply expert reports served by early 2019, including Celgene press releases disclosing lenalidomide + dexamethasone dosing) never reached judgment either.
4. Claim text provenance. The page supplied to us is truncated before the claims. Claims 1 and 13 above are reproduced from the Board's institution decision (Paper 7), which quotes them verbatim and identifies them as the only independent claims; dependent-claim wording is taken from the IPR petition's claim-by-claim analysis. I regard this as reliable but not a substitute for the printed claim set — verify against the USPTO PatentCenter copy if exact language is dispositive. Note also the Certificate of Correction recorded at column 32 of the printed patent, which the Board cited alongside both independent claims; it was not available to me and could affect exact wording.

---

X. Bottom line

Under § 103, US 7,968,569 is highly vulnerable on obviousness, but the vulnerability is concentrated in a specific place. The compound (lenalidomide), its 5–25 mg human dosing, its use in multiple myeloma, its superiority to thalidomide, and its combination with 40 mg/day dexamethasone were all disclosed or claimed before the 2002 priority date — most damningly in Celgene's own U.S. Pat. No. 6,281,230 ('230), which claims lenalidomide 1–100 mg plus a steroid such as dexamethasone for cancer, and in the 8 May 2001 Celgene press release, which reports the 5/10/25 mg cohorts, the >60% response rate, and that "REVIMID up to 25 mg per day was well tolerated." The recited 28-day cycle and 40 mg/day dexamethasone pulses are the Palumbo 2001 protocol almost verbatim; claim 13's "days 1–4 every 28 days" is literally a subset of Palumbo's days 1–4/9–12/17–20 schedule.

The only limitation with no express disclosure is the 21 consecutive days on / 7 days off rest period. A PHOSITA could readily have arrived at it — myelosuppression was the known dose-limiting toxicity of the compound, the specification itself recites the standard rationale for cycling therapy, and 28-day cycles with a rest were conventional in MM — but the record also contains a genuine teaching-away datum (the DeVita "familiar 2-week interval," and MM literature using ≥3-week rests). That is why the Board found the pleaded grounds fell short of a reasonable likelihood and why the patent survived — not because it was adjudicated valid, but because it was never adjudicated.

Strongest single ground, restated for a § 103 challenge: U.S. Pat. No. 6,281,230 ('230) in view of the Celgene 8 May 2001 press release, in view of Palumbo et al. (Haematologica 2001), and, if necessary, further in view of Gordon, Myelosuppression (4th ed. 2001) and DeVita, Principles of Chemotherapy (1993) for the rest-period motivation. That combination supplies every element of claims 1–12 and 14–15 and leaves only the 7-day (rather than 14-day) rest duration to routine optimization — the weakest, but not insurmountable, point in the chain.

Primary sources: IPR2018-01714 Petition · Institution Decision, 14 Mar. 2019 · Patent Owner Preliminary Response · Dr. Tricot Declaration / exhibit list · Celgene Press Release, 8 May 2001 (Ex. 1012) · Celgene Press Release, 11 Dec. 2001 (IPR2018-01509 Ex. 1012) · Celgene v. Lotus/Alvogen, 2:17-cv-06842 opinion